Association of Intrahepatic Cholestasis of Pregnancy and Chronic Placental Inflammation

NCT ID: NCT05197387

Last Updated: 2024-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

322 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-21

Study Completion Date

2025-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational prospective study will help to determine if an immune process similar to allograft rejection is responsible for the occurrence of an intrahepatic cholestasis of pregnancy (ICP).

If so, it would suggest the potential benefit of immunomodulatory therapeutics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study will include 322 pregnant women at delivery: 161 women diagnosed with an intrahepatic cholestasis of pregnancy, and 161 control women.

A blood test will be performed at delivery for each woman and each newborn, in order to measure several biological parameters involved in inflammation processes, allograft rejection and angiogenesis. Placenta will also be analysed. In particular, we will look for chronic inflammation in placenta.

Biological parameters and placental parameters will be compared between the two groups: cases with ICP and controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholestasis of Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Women with intrahepatic cholestasis of pregnancy

No interventions assigned to this group

Controls

Women without intrahepatic cholestasis of pregnancy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult pregnant woman with singleton

For cases: diagnosis of intrahepatic cholestasis of pregnancy For controls: no diagnosis of ICP

Exclusion Criteria

* Women under 18 years old
* Women under legal protection
* Gemellar pregnancies
* Delivery before 22 Weeks of gestation
* Medical termination of pregnancy
* Acute chorioamniotitis, in particular those due to the following pathogens: toxoplasmosis, rubella, CMV, herpes virus
* Premature rupture of membranes \<37SA
* Women infected by covid-19 in the month before delivery
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Angers

Angers, , France

Site Status NOT_YET_RECRUITING

Polyclinique KERAUDREN

Brest, , France

Site Status RECRUITING

CHU de Brest

Brest, , France

Site Status RECRUITING

CHU de Caen

Caen, , France

Site Status RECRUITING

CH de Chambery

Chambéry, , France

Site Status RECRUITING

CH Bretagne Sud

Lorient, , France

Site Status RECRUITING

CHU Nantes

Nantes, , France

Site Status RECRUITING

CH de Quimper

Quimper, , France

Site Status RECRUITING

CHU de Rennes

Rennes, , France

Site Status RECRUITING

CH St Brieuc

Saint-Brieuc, , France

Site Status RECRUITING

CHU de Tours

Tours, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Claire de Moreuil

Role: CONTACT

02 98 14 53 03

Philippe Merviel

Role: CONTACT

02-98-22-39-70

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Véronique BEAUDOUX

Role: primary

Maryline Maryline Pluchon

Role: primary

Claire de Moreuil

Role: primary

Pr

Role: backup

Karine MORCEL, [email protected]

Role: backup

Michel Dreyfus

Role: primary

Emmanuel Decroisette

Role: primary

Stéphanie Pittion-Quiniou

Role: primary

Norbert WINER

Role: primary

Morgane VINCKE

Role: backup

Camille SAUVEE

Role: primary

Linda Lassel

Role: primary

Claire COMBESCURE

Role: primary

Franck Perrotin

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Du Q, Pan Y, Zhang Y, Zhang H, Zheng Y, Lu L, Wang J, Duan T, Chen J. Placental gene-expression profiles of intrahepatic cholestasis of pregnancy reveal involvement of multiple molecular pathways in blood vessel formation and inflammation. BMC Med Genomics. 2014 Jul 7;7:42. doi: 10.1186/1755-8794-7-42.

Reference Type BACKGROUND
PMID: 25001852 (View on PubMed)

Patel S, Pinheiro M, Felix JC, Opper N, Ouzounian JG, Lee RH. A case-control review of placentas from patients with intrahepatic cholestasis of pregnancy. Fetal Pediatr Pathol. 2014 Aug;33(4):210-5. doi: 10.3109/15513815.2014.899413. Epub 2014 Apr 23.

Reference Type BACKGROUND
PMID: 24758367 (View on PubMed)

Larson SP, Kovilam O, Agrawal DK. Immunological basis in the pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Clin Immunol. 2016;12(1):39-48. doi: 10.1586/1744666X.2016.1101344. Epub 2015 Oct 15.

Reference Type BACKGROUND
PMID: 26469633 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INTREPIDE (29BRC21.0188)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hydroxychloroquine for Prevention of Recurrent Miscarriage.
NCT03165136 ACTIVE_NOT_RECRUITING PHASE3
IBD Pregnancy Registry
NCT06910553 RECRUITING